Ye Zi, Liu Runqing, Wang Hangxing, Zuo Aizhen, Jin Cen, Wang Nan, Sun Huiqi, Feng Luqian, Yang Hua
The Clinical Medical College, Guizhou Medical University, Guiyang, Guizhou Province, China.
Division of Infectious Diseases, Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Neural Regen Res. 2025 Aug 1;20(8):2199-2217. doi: 10.4103/NRR.NRR-D-23-01985. Epub 2024 Jul 29.
Reperfusion following cerebral ischemia causes both structural and functional damage to brain tissue and could aggravate a patient's condition; this phenomenon is known as cerebral ischemia-reperfusion injury. Current studies have elucidated the neuroprotective role of the sirtuin protein family (Sirtuins) in modulating cerebral ischemia-reperfusion injury. However, the potential of utilizing it as a novel intervention target to influence the prognosis of cerebral ischemia-reperfusion injury requires additional exploration. In this review, the origin and research progress of Sirtuins are summarized, suggesting the involvement of Sirtuins in diverse mechanisms that affect cerebral ischemia-reperfusion injury, including inflammation, oxidative stress, blood-brain barrier damage, apoptosis, pyroptosis, and autophagy. The therapeutic avenues related to Sirtuins that may improve the prognosis of cerebral ischemia-reperfusion injury were also investigated by modulating Sirtuins expression and affecting representative pathways, such as nuclear factor-kappa B signaling, oxidative stress mediated by adenosine monophosphate-activated protein kinase, and the forkhead box O. This review also summarizes the potential of endogenous substances, such as RNA and hormones, drugs, dietary supplements, and emerging therapies that regulate Sirtuins expression. This review also reveals that regulating Sirtuins mitigates cerebral ischemia-reperfusion injury when combined with other risk factors. While Sirtuins show promise as a potential target for the treatment of cerebral ischemia-reperfusion injury, most recent studies are based on rodent models with circadian rhythms that are distinct from those of humans, potentially influencing the efficacy of Sirtuins-targeting drug therapies. Overall, this review provides new insights into the role of Sirtuins in the pathology and treatment of cerebral ischemia-reperfusion injury.
脑缺血后的再灌注会对脑组织造成结构和功能损伤,并可能加重患者病情;这种现象被称为脑缺血-再灌注损伤。目前的研究已经阐明了沉默调节蛋白家族(Sirtuins)在调节脑缺血-再灌注损伤中的神经保护作用。然而,将其作为影响脑缺血-再灌注损伤预后的新型干预靶点的潜力仍需进一步探索。在这篇综述中,总结了Sirtuins的起源和研究进展,提示Sirtuins参与了影响脑缺血-再灌注损伤的多种机制,包括炎症、氧化应激、血脑屏障损伤、细胞凋亡、焦亡和自噬。还通过调节Sirtuins表达并影响代表性途径,如核因子-κB信号通路、由腺苷单磷酸激活蛋白激酶介导的氧化应激以及叉头框O,研究了与Sirtuins相关的可能改善脑缺血-再灌注损伤预后的治疗途径。这篇综述还总结了内源性物质(如RNA和激素)、药物、膳食补充剂以及调节Sirtuins表达的新兴疗法的潜力。这篇综述还揭示,当与其他危险因素结合时,调节Sirtuins可减轻脑缺血-再灌注损伤。虽然Sirtuins有望成为治疗脑缺血-再灌注损伤的潜在靶点,但最近的大多数研究基于与人类昼夜节律不同的啮齿动物模型,这可能会影响以Sirtuins为靶点的药物治疗的疗效。总体而言,这篇综述为Sirtuins在脑缺血-再灌注损伤的病理和治疗中的作用提供了新的见解。